Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac ...

Here the authors use X-ray crystallography to identify a TCR that contacts only the MHC beta chain of HLA-DQ2, with this specificity potentially enforced by Leucine-55 of HLA-DQ2.5 to exclude ...